Literature DB >> 16628582

Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine.

Boulos Botros1, Adel Omar, Khairat Elian, Gihan Mohamed, Atef Soliman, Adel Salib, Diaa Salman, Magdi Saad, Kenneth Earhart.   

Abstract

Three hundred eighteen European cows and 115 buffaloes were vaccinated with locally prepared Smithburn vaccine, of which, 100 cows and 20 buffaloes were pregnant. Twenty-eight cows aborted within 72 days post-vaccination, buffaloes did not abort. Blood samples collected 77 days post-vaccination from aborted cows, 17 pregnant cows, 5 pregnant buffaloes, and 32 non-pregnant cows. Sera were tested by ELISA for anti-RVF IgM and IgG. All aborted cows were strongly positive for IgG. Five of 17 cows and two of five buffaloes that did not abort were IgG positive. The percentage of IgM positives in aborted cows was 25% and 0% in non-aborted cows. The percentage of IgG positives in pregnant non-aborted cows was lower than in non-pregnant cows. The percentage of IgG positives of non-pregnant cows was lower than pregnant aborted cows. Virus was isolated from one aborted fetus. The nucleotide sequence of fetus virus was compared to Smithburn of Onderstepoort, local Smithburn and virus isolates from 1993 to 1994 and 1977 RVF outbreaks. The nucleotide sequences of Onderstepoort and Egyptian Smithburn vaccines were almost identical. The sequences of 1993-1994 isolates were identical to 1977 outbreak virus. Virus from the fetus had two mutations; it is apparently a variant that is genetically distant from local Smithburn and Onderstepoort vaccines. Fetus virus was genetically distant from virus of 1993/1994 and 1977 outbreaks. In conclusion, antibody response to vaccination with local Smithburn had occurred in some, but not all the cows and buffaloes. Virus isolation from the fetus suggests in utero transmission of used vaccine virus, which resulted in high abortions in European cows.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16628582     DOI: 10.1002/jmv.20624

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  48 in total

1.  Rift Valley fever virus structural and nonstructural proteins: recombinant protein expression and immunoreactivity against antisera from sheep.

Authors:  Bonto Faburay; William Wilson; D Scott McVey; Barbara S Drolet; Hana Weingartl; Daniel Madden; Alan Young; Wenjun Ma; Juergen A Richt
Journal:  Vector Borne Zoonotic Dis       Date:  2013-08-20       Impact factor: 2.133

Review 2.  Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.

Authors:  Tetsuro Ikegami
Journal:  Expert Rev Vaccines       Date:  2017-05-02       Impact factor: 5.217

3.  Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR.

Authors:  Shoko Nishiyama; Olga A L Slack; Nandadeva Lokugamage; Terence E Hill; Terry L Juelich; Lihong Zhang; Jennifer K Smith; David Perez; Bin Gong; Alexander N Freiberg; Tetsuro Ikegami
Journal:  Virulence       Date:  2016-06-01       Impact factor: 5.882

4.  Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge.

Authors:  Kimberly A Dodd; Brian H Bird; Maureen G Metcalfe; Stuart T Nichol; César G Albariño
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

5.  Structures of phlebovirus glycoprotein Gn and identification of a neutralizing antibody epitope.

Authors:  Yan Wu; Yaohua Zhu; Feng Gao; Yongjun Jiao; Babayemi O Oladejo; Yan Chai; Yuhai Bi; Shan Lu; Mengqiu Dong; Chang Zhang; Guangmei Huang; Gary Wong; Na Li; Yanfang Zhang; Yan Li; Wen-Hai Feng; Yi Shi; Mifang Liang; Rongguang Zhang; Jianxun Qi; George F Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-21       Impact factor: 11.205

6.  A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity.

Authors:  David H Holman; Adam Penn-Nicholson; Danher Wang; Jan Woraratanadharm; Mary-Katherine Harr; Min Luo; Ellen M Maher; Michael R Holbrook; John Y Dong
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

7.  Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus.

Authors:  Nitin Bhardwaj; Mark T Heise; Ted M Ross
Journal:  PLoS Negl Trop Dis       Date:  2010-06-22

8.  Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention.

Authors:  Michel Pepin; Michele Bouloy; Brian H Bird; Alan Kemp; Janusz Paweska
Journal:  Vet Res       Date:  2010 Nov-Dec       Impact factor: 3.683

9.  Rift Valley Fever - assessment of effectiveness of surveillance and control measures in the EU.

Authors:  Søren Saxmose Nielsen; Julio Alvarez; Dominique Joseph Bicout; Paolo Calistri; Klaus Depner; Julian Ashley Drewe; Bruno Garin-Bastuji; José Luis Gonzales Rojas; Christian Gortázar Schmidt; Mette Herskin; Virginie Michel; Miguel Ángel Miranda Chueca; Paolo Pasquali; Helen Clare Roberts; Liisa Helena Sihvonen; Karl Stahl; Antonio Velarde Calvo; Arvo Viltrop; Christoph Winckler; Simon Gubbins; Sotiria-Eleni Antoniou; Alessandro Broglia; Josè Cortiñas Abrahantes; Sofie Dhollander; Yves Van der Stede
Journal:  EFSA J       Date:  2020-11-05

10.  Development of a RVFV ELISA that can distinguish infected from vaccinated animals.

Authors:  Anita K McElroy; César G Albariño; Stuart T Nichol
Journal:  Virol J       Date:  2009-08-13       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.